Exactech Announces Completion of Corporate Integrity Agreement Requirements
March 10 2016 - 1:00PM
Business Wire
Exactech Inc. (Nasdaq:EXAC), a developer and producer of bone
and joint restoration products for extremities, knee, hip, spine
and biologic materials, announced today that it has completed the
requirements of its five-year Corporate Integrity Agreement (CIA)
between the Office of Inspector General and the Department of
Health and Human Services.
“We are pleased to have completed the requirements of the CIA,”
said Exactech Chief Executive Officer David Petty. “Maintaining the
highest standards of ethics and compliance is an integral part of
our corporate culture and we will continue to honor this commitment
through comprehensive, effective and efficient compliance
programs.”
About Exactech
Based in Gainesville, Fla., Exactech develops and markets
orthopaedic implant devices, related surgical instruments and
biologic materials and services to hospitals and physicians. The
company manufactures many of its orthopaedic devices at its
Gainesville facility. Exactech’s orthopaedic products are used in
the restoration of bones and joints that have deteriorated as a
result of injury or diseases such as arthritis. Exactech markets
its products in the United States, in addition to more than 30
markets in Europe, Latin America, Asia and the Pacific. Additional
information about Exactech, Inc. can be found at
http://www.exac.com. Copies of Exactech’s press releases, SEC
filings, current price quotes and other valuable information for
investors may be found at http://www.exac.com and
http://www.hawkassociates.com.
An investment profile on Exactech may be found at
http://www.hawkassociates.com/profile/exac.cfm. To receive future
releases in e-mail alerts, sign up at
http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which represent
the company’s expectations or beliefs concerning future events of
the company’s financial performance. These forward-looking
statements are further qualified by important factors that could
cause actual results to differ materially from those in the
forward-looking statements. These factors include the effect of
competitive pricing, the company’s dependence on the ability of
third party manufacturers to produce components on a basis which is
cost-effective to the company, market acceptance of the company’s
products and the effects of government regulation. Results actually
achieved may differ materially from expected results included in
these statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160310006067/en/
Exactech Inc.Investor contactsJody Phillips,
352-377-1140Executive Vice President of Finance & Chief
Financial OfficerorHawk AssociatesJulie Marshall or Frank Hawkins,
305-451-1888E-mail: EXAC@hawkassociates.comorMedia contactPriscilla
Bennett, 352-377-1140Vice President, Corporate & Marketing
Communication
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Sep 2023 to Sep 2024